ClinicalTrials.gg
CompletedNCT02679079Updated Jan 15, 2021Results posted

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

A Phase 2 interventional study of NBI-98854 and Placebo in Tourette Syndrome, sponsored by Neurocrine Biosciences. Completed at 44 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
29th of 105
98 · median 33
Started
2016
with 4 others
Phase 2
26 of 139
4 open now
Registered
74th of 139
by date
Lead sponsor
8 of 139
Neurocrine Biosciences

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 29th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2016, is one of 26 in phase 2, and was the 74th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment. This study will enroll approximately 90 male and female pediatric subjects clinically diagnosed with Tourette Syndrome.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of Tourette Syndrome (TS)
  2. Have at least moderate tic severity
  3. Have TS symptoms that impair school, occupational, and/or social function
  4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g. obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]), be on stable doses
  5. Be in good general health
  6. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids and a negative alcohol screen
  7. Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month prior to screening
  2. Have a known history of long syndrome or cardiac arrhythmia
  3. Have a known history of neuroleptic malignant syndrome
  4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
  5. Have an allergy, , or intolerance to VMAT2 inhibitors
  6. Have a blood loss ≥250 mL or donated blood within 30 days prior to screening
  7. Have a known history of substance dependence, substance (drug) or alcohol abuse
  8. Have a significant risk of suicidal or violent behavior
  9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or at baseline or plan to initiate CBIT during the study
  10. Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Administered once daily for 6 weeks

    Drug: Placebo

  • Experimental
    Dose Group 1

    Administered once daily for 6 weeks

    Drug: NBI-98854

  • Experimental
    Dose Group 2

    Administered once daily for 6 weeks

    Drug: NBI-98854

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)

    The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Clinical Global Impression of Tourette Syndrome (CGI-TS) - Improvement Score at Week 6

    The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. Each of the CGI-TS-Improvement response categories was assigned a numerical score as follows: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = Not changed; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.

    Time frame: Week 6

  2. Participants Who Are a YGTSS TTS Responder at Week 6

    A TTS responder is defined, on a per-visit basis, as a participant whose TTS value is reduced by at least 30% from baseline at the specified postbaseline visit.

    Time frame: Baseline, Week 6

  3. Change From Baseline to Week 6 in the YGTSS Impairment Score

    The YGTSS Impairment item is used to rate impairment due to tics using the following 50-point anchored scale: 0 = None; 10 = Minimal; 20 = Mild; 30 = Moderate; 40 = Marked; 50 = Severe.

    Time frame: Baseline, Week 6

  4. Change From Baseline to Week 6 in the YGTSS Global Tic Severity Score

    The YGTSS Global Tic Severity score is the sum of the YGTSS TTS and the YGTSS Impairment score and ranges from 0 to 100, with higher scores representing greater severity.

    Time frame: Baseline, Week 6

  5. Change From Baseline to Week 6 in the Rush Video-based Tic Rating Scale (RTRS) Total Score

    A modified RTRS was used in this study that includes short video recordings to measure 5 tic variables: number of body areas affected, frequency of motor and phonic tics, and severity of motor and phonic tics. The RTRS total score is calculated as the sum of the 5 domain scores, and ranges from 0 to 20, with higher scores representing greater severity. The final on-treatment visit was used in participants who discontinued prior to Week 6.

    Time frame: Baseline, Week 6

  6. Change From Baseline to Week 6 in the Premonitory Urge for Tics Scale (PUTS) Total Score

    The PUTS is an instrument for quantifying the premonitory urge phenomena associated with tics. It consists of 9 items, each of which is scored on a 4-point scale (1=not at all true, 2=a little true, 3=pretty much true, 4=very much true). The PUTS total score is calculated as the sum of the scores for the 9 items. The total score ranges from 9 to 36, with higher scores indicating a worse outcome.

    Time frame: Baseline, Week 6

  7. Change From Baseline to Week 6 in the Clinical Global Impression of Tics (CGI-Tics) - Severity Score

    The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

    Time frame: Baseline, Week 6

  8. Participants Who Are a CGI-TS-Improvement Responder at Week 6

    A participant is classified as a CGI-TS-Improvement responder at a given visit if their CGI-TS-Improvement score is either a "1" ("very much improved") or a "2" ("much improved") at the visit.

    Time frame: Week 6

07

Results

Posted Jan 15, 2021

Participant flow

This study enrolled participants (male and female), 6 to 17 years of age, with a diagnosis of Tourette Syndrome through Diagnostic and Statistical Manual of Mental Disorders, 4th or 5th Editions (DSM-IV or -V) from 30 study centers in the United States. The first participant was enrolled on 23 March 2016 and last participant completed the study on 14 April 2017.

Participant flow — Overall Study
MilestonePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Started333233
Itt analysis set313232
Completed293031
Not completed422
Withdrew: Adverse event202
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject210

Outcome measures

PrimaryChange From Baseline to Week 6 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)

The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Score on scale
Change From Baseline to Week 6 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
Score on scalePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Change From Baseline to Week 6 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)-8.8 ± 1.5-7.3 ± 1.4-9.1 ± 1.4
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Mixed Models Analysis · p = 0.89 (Nominal p-value is considered statistically significant if less than 0.05. To control for multiplicity, comparisons were tested sequentially.) · Mean difference (net): -0.3 · 95% CI -4.4 to 3.8
  • Placebo vs NBI-98854 Low Dose · Mixed Models Analysis · p = 0.47 (To control for multiplicity, comparisons were tested sequentially. Nominal p-value was not evaluated for statistical significance since first comparison was not statistically significant.) · Mean difference (net): 1.5 · 95% CI -2.6 to 5.6
SecondaryClinical Global Impression of Tourette Syndrome (CGI-TS) - Improvement Score at Week 6

The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. Each of the CGI-TS-Improvement response categories was assigned a numerical score as follows: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = Not changed; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.

Time frame:
Week 6
Reported as:
Least squares mean · Score on scale
Clinical Global Impression of Tourette Syndrome (CGI-TS) - Improvement Score at Week 6
Score on scalePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Clinical Global Impression of Tourette Syndrome (CGI-TS) - Improvement Score at Week 63.4 ± 0.23.5 ± 0.23.0 ± 0.2
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Mixed Models Analysis · p = 0.21 (To control for multiplicity, comparisons were tested sequentially. Nominal p-value was not evaluated for statistical significance since first comparison was not statistically significant.) · Mean difference (net): -0.4 · 95% CI -1.0 to 0.2
  • Placebo vs NBI-98854 Low Dose · Mixed Models Analysis · p = 0.67 (To control for multiplicity, comparisons were tested sequentially. Nominal p-value was not evaluated for statistical significance since first comparison was not statistically significant.) · Mean difference (net): 0.1 · 95% CI -0.5 to 0.8
SecondaryParticipants Who Are a YGTSS TTS Responder at Week 6

A TTS responder is defined, on a per-visit basis, as a participant whose TTS value is reduced by at least 30% from baseline at the specified postbaseline visit.

Time frame:
Baseline, Week 6
Reported as:
Count of participants · Participants
Participants Who Are a YGTSS TTS Responder at Week 6
ParticipantsPlaceboNBI-98854 Low DoseNBI-98854 High Dose
Participants Who Are a YGTSS TTS Responder at Week 610915
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Cochran-Mantel-Haenszel · p = 0.24 (Comparison was not included in multiplicity adjustment procedure.) · Risk difference (rd): 13.9Risk difference expressed as percentage.
  • Placebo vs NBI-98854 Low Dose · Cochran-Mantel-Haenszel · p = 0.71 (Comparison was not included in multiplicity adjustment procedure.) · Risk difference (rd): -4.5Risk difference expressed as a percentage.
SecondaryChange From Baseline to Week 6 in the YGTSS Impairment Score

The YGTSS Impairment item is used to rate impairment due to tics using the following 50-point anchored scale: 0 = None; 10 = Minimal; 20 = Mild; 30 = Moderate; 40 = Marked; 50 = Severe.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Score on scale
Change From Baseline to Week 6 in the YGTSS Impairment Score
Score on scalePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Change From Baseline to Week 6 in the YGTSS Impairment Score-8.5 ± 2.1-7.1 ± 2.1-10.4 ± 2.0
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Mixed Models Analysis · p = 0.52 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): -1.9 · 95% CI -7.7 to 3.9
  • Placebo vs NBI-98854 Low Dose · Mixed Models Analysis · p = 0.64 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): 1.4 · 95% CI -4.5 to 7.2
SecondaryChange From Baseline to Week 6 in the YGTSS Global Tic Severity Score

The YGTSS Global Tic Severity score is the sum of the YGTSS TTS and the YGTSS Impairment score and ranges from 0 to 100, with higher scores representing greater severity.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Score on scale
Change From Baseline to Week 6 in the YGTSS Global Tic Severity Score
Score on scalePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Change From Baseline to Week 6 in the YGTSS Global Tic Severity Score-17.2 ± 3.2-14.4 ± 3.1-19.5 ± 3.1
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Mixed Models Analysis · p = 0.60 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): -2.3 · 95% CI -11.2 to 6.5
  • Placebo vs NBI-98854 Low Dose · Mixed Models Analysis · p = 0.54 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): 2.8 · 95% CI -6.1 to 11.7
SecondaryChange From Baseline to Week 6 in the Rush Video-based Tic Rating Scale (RTRS) Total Score

A modified RTRS was used in this study that includes short video recordings to measure 5 tic variables: number of body areas affected, frequency of motor and phonic tics, and severity of motor and phonic tics. The RTRS total score is calculated as the sum of the 5 domain scores, and ranges from 0 to 20, with higher scores representing greater severity. The final on-treatment visit was used in participants who discontinued prior to Week 6.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Score on scale
Change From Baseline to Week 6 in the Rush Video-based Tic Rating Scale (RTRS) Total Score
Score on scalePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Change From Baseline to Week 6 in the Rush Video-based Tic Rating Scale (RTRS) Total Score-1.2 ± 0.8-1.6 ± 0.8-1.7 ± 0.7
Statistical analysis
  • Placebo vs NBI-98854 High Dose · ANCOVA · p = 0.64 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): -0.5 · 95% CI -2.6 to 1.6
  • Placebo vs NBI-98854 Low Dose · ANCOVA · p = 0.77 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): -0.3 · 95% CI -2.5 to 1.9
SecondaryChange From Baseline to Week 6 in the Premonitory Urge for Tics Scale (PUTS) Total Score

The PUTS is an instrument for quantifying the premonitory urge phenomena associated with tics. It consists of 9 items, each of which is scored on a 4-point scale (1=not at all true, 2=a little true, 3=pretty much true, 4=very much true). The PUTS total score is calculated as the sum of the scores for the 9 items. The total score ranges from 9 to 36, with higher scores indicating a worse outcome.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Score on scale
Change From Baseline to Week 6 in the Premonitory Urge for Tics Scale (PUTS) Total Score
Score on scalePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Change From Baseline to Week 6 in the Premonitory Urge for Tics Scale (PUTS) Total Score-0.6 ± 0.8-1.0 ± 0.80.3 ± 0.8
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Mixed Models Analysis · p = 0.45 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): 0.9 · 95% CI -1.4 to 3.2
  • Placebo vs NBI-98854 Low Dose · Mixed Models Analysis · p = 0.72 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): -0.4 · 95% CI -2.7 to 1.9
SecondaryChange From Baseline to Week 6 in the Clinical Global Impression of Tics (CGI-Tics) - Severity Score

The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Score on scale
Change From Baseline to Week 6 in the Clinical Global Impression of Tics (CGI-Tics) - Severity Score
Score on scalePlaceboNBI-98854 Low DoseNBI-98854 High Dose
Change From Baseline to Week 6 in the Clinical Global Impression of Tics (CGI-Tics) - Severity Score-1.1 ± 0.2-0.5 ± 0.2-0.9 ± 0.2
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Mixed Models Analysis · p = 0.41 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): 0.2 · 95% CI -0.3 to 0.7
  • Placebo · Mixed Models Analysis · p = 0.01 (Comparison was not included in multiplicity adjustment procedure.) · Mean difference (net): 0.6 · 95% CI 0.2 to 1.1
SecondaryParticipants Who Are a CGI-TS-Improvement Responder at Week 6

A participant is classified as a CGI-TS-Improvement responder at a given visit if their CGI-TS-Improvement score is either a "1" ("very much improved") or a "2" ("much improved") at the visit.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Participants Who Are a CGI-TS-Improvement Responder at Week 6
ParticipantsPlaceboNBI-98854 Low DoseNBI-98854 High Dose
Participants Who Are a CGI-TS-Improvement Responder at Week 66611
Statistical analysis
  • Placebo vs NBI-98854 High Dose · Cochran-Mantel-Haenszel · p = 0.18 (Comparison was not included in multiplicity adjustment procedure.) · Risk difference (rd): 14.8Risk difference expressed as a percentage.
  • Placebo vs NBI-98854 Low Dose · Cochran-Mantel-Haenszel · p = 0.95 (Comparison was not included in multiplicity adjustment procedure.) · Risk difference (rd): -0.7Risk difference expressed as a percentage.

Adverse events

Collected over Up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/32 (0%)1/32 (3.1%)9/32 (28.1%)
NBI-98854 Low Dose0/32 (0%)0/32 (0%)15/32 (46.9%)
NBI-98854 High Dose0/33 (0%)0/33 (0%)19/33 (57.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboNBI-98854 Low DoseNBI-98854 High Dose
Conversion disorderPsychiatric disorders1/320/320/33
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboNBI-98854 Low DoseNBI-98854 High Dose
HeadacheNervous system disorders3/326/323/33
Upper respiratory tract infectionInfections and infestations0/321/325/33
SomnolenceNervous system disorders1/324/323/33
IrritabilityGeneral disorders3/322/322/33
SedationNervous system disorders0/322/323/33
InsomniaPsychiatric disorders1/322/323/33
TicPsychiatric disorders2/321/321/33
VomitingGastrointestinal disorders1/322/321/33
Abdominal pain upperGastrointestinal disorders1/322/320/33
NauseaGastrointestinal disorders2/320/321/33

Baseline characteristics

The intent-to-treat (ITT) analysis set included all randomized participants who received at least one dose of study drug, had postbaseline safety data, and had a baseline (Day -1) and at least one postrandomization Total Tic Score (TTS) value reported at a scheduled or mapped early termination (ET) visit during the 6 week treatment period.

Age, Continuous
Age, Continuous(Years)PlaceboNBI-98854 Low DoseNBI-98854 High DoseTotal
Mean11.5 (7 to 15)12.0 (6 to 17)11.6 (6 to 17)11.7 (6 to 17)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNBI-98854 Low DoseNBI-98854 High DoseTotal
Female411520
Male27212775
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNBI-98854 Low DoseNBI-98854 High DoseTotal
Hispanic or Latino54211
Not Hispanic or Latino26283084
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboNBI-98854 Low DoseNBI-98854 High DoseTotal
American Indian or Alaska Native0011
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2125
White27312987
More than one race2002
Unknown or Not Reported0000
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)(Score on scale)PlaceboNBI-98854 Low DoseNBI-98854 High DoseTotal
Mean30.4 (9 to 44)32.8 (23 to 49)32.9 (24 to 47)32.1 (9 to 49)
08

Study locations

44 sites
  • Sun City, Arizona, United States
  • Springdale, Arkansas, United States
  • Long Beach, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • Upland, California, United States
  • Bradenton, Florida, United States
  • Gainesville, Florida, United States
  • Hialeah, Florida, United States
  • Loxahatchee Groves, Florida, United States
  • Melbourne, Florida, United States
  • Orlando, Florida, United States
  • Saint Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Naperville, Illinois, United States
  • Wichita, Kansas, United States
  • Boston, Massachusetts, United States
  • Natick, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Bloomfield Hills, Michigan, United States
  • Lincoln, Nebraska, United States
  • Nashua, New Hampshire, United States
  • Marlton, New Jersey, United States
  • Summit, New Jersey, United States
  • Manhasset, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Cincinnati, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Franklin, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • DeSoto, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Irving, Texas, United States
  • Orem, Utah, United States
  • Salt Lake City, Utah, United States
  • Kirkland, Washington, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Apr 2017, 12 months.

Results were first posted in Jan 2021, 3 years 9 months after primary completion. A results delay was requested in Sep 2018.

Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Feb 10, 2016
StartActual
Mar 23, 2016
Primary completionActual
Apr 14, 2017
CompletionActual
Apr 14, 2017
Results delay requested
Sep 7, 2018
Results first posted
Jan 15, 2021
Last update
Jan 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02679079
Responsible party
Sponsor
First posted
Feb 10, 2016
Start date
Mar 23, 2016
Primary completion
Apr 14, 2017
Completion
Apr 14, 2017
Results posted
Jan 15, 2021
Last update
Jan 15, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion